---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-032505"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2026-10-13T12:41:52+00:00"
generated_at: "2026-10-13T12:45:05.029951+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Phio completes first commercial-scale cGMP batch of PH-762; Phase 2b trial set for Q1 2027

## Summary
- PH-762 drug substance (API) batch released meeting established specs, confirmed by Certificate of Analysis and Certificate of Compliance.
- Manufactured under cGMP, the approved Master Batch Record and ICH Q7 guidelines, per the October 13, 2026 press release.
- Validated material moves to final drug product completion for Phio's planned Phase 2b clinical study, expected to begin Q1 2027.
- CEO Robert Bitterman said the milestone culminates a complex 16-month cross-functional effort and mitigates key development and manufacturing risks.
- Phio is a clinical-stage biotech developing cancer therapeutics on its INTASYL siRNA gene-silencing platform; PH-762 is the lead program.

## SEC filing metadata
- accession: 0001437749-26-032505
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2026-10-13T12:41:52+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000143774926032505/0001437749-26-032505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000143774926032505/phio20261008_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-032505
- JSON: https://secwatch.observer/filing/0001437749-26-032505.json
- Plain text: https://secwatch.observer/filing/0001437749-26-032505.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.